View Financial HealthNascent Biotech 배당 및 자사주 매입배당 기준 점검 0/6Nascent Biotech 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.공시 • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.공시 • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0공시 • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.공시 • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.공시 • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.공시 • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.공시 • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.공시 • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.공시 • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.공시 • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NBIO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NBIO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Nascent Biotech 배당 수익률 vs 시장NBIO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NBIO)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (NBIO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NBIO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NBIO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NBIO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NBIO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/07 10:40종가2026/06/02 00:00수익2024/06/30연간 수익2024/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nascent Biotech, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.
공시 • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.
공시 • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0
공시 • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.
공시 • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
공시 • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
공시 • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.
공시 • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.
공시 • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
공시 • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.
공시 • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors.